97 related articles for article (PubMed ID: 6848203)
1. Disposition of bisantrene in humans and rabbits: evidence for intravascular deposition of drug as a cause of phlebitis.
Powis G; Kovach JS
Cancer Res; 1983 Feb; 43(2):925-9. PubMed ID: 6848203
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical investigation of 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride with correlative in vitro human tumor clonogenic assay.
Alberts DS; Mackel C; Pocelinko R; Salmon SE
Cancer Res; 1982 Mar; 42(3):1170-5. PubMed ID: 7037174
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacokinetics of 9, 10-anthracenedicarboxaldehyde-bis [(4,5-dihydro-1 H-imidazol-2-yl)hydrazone]dihydrochloride.
Lu K; Savaraj N; Yap BS; Feun LG; Umsawasdi T; Loo TL
Cancer Chemother Pharmacol; 1986; 16(2):156-9. PubMed ID: 3948302
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical evaluation of 9,10-anthracenedicarboxyaldehyde[bis(4,5-dihydro-1H-imidazol-2-yl)hydrazone]dihydrochloride (bisantrene).
Yap BS; Yap HY; Blumenschein GR; Bedikian AY; Pocelinko R; Bodey GP
Cancer Treat Rep; 1982 Jul; 66(7):1517-20. PubMed ID: 7093967
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolic profile of a new antitumor agent: CL 216,942 (bisantrene) in laboratory animals.
Wu WH; Nicolau G
Cancer Treat Rep; 1982 May; 66(5):1173-85. PubMed ID: 7083220
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the pharmacokinetics of bisantrene (NSC-337766).
Kuhn JG; Ludden TM; Myers JW; Von Hoff DD
Invest New Drugs; 1983; 1(3):253-7. PubMed ID: 6678875
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of intraarterial cis-diamminedichloroplatinum(II).
Stewart DJ; Benjamin RS; Zimmerman S; Caprioli RM; Wallace S; Chuang V; Calvo D; Samuels M; Bonura J; Loo TL
Cancer Res; 1983 Feb; 43(2):917-20. PubMed ID: 6681533
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vincristine sulfate in adult cancer patients.
Sethi VS; Jackson DV; White DR; Richards F; Stuart JJ; Muss HB; Cooper MR; Spurr CL
Cancer Res; 1981 Sep; 41(9 Pt 1):3551-5. PubMed ID: 7260915
[TBL] [Abstract][Full Text] [Related]
9. A phase I and pharmacokinetic comparison of hepatic arterial and peripheral vein infusions of bisantrene for liver cancer.
Weiss GR; Hersh M; Kuhn JG; Ludden TM; von Hoff DD; Kisner DL; Pirtle TE
Cancer Chemother Pharmacol; 1985; 15(2):144-8. PubMed ID: 4017163
[TBL] [Abstract][Full Text] [Related]
10. Regional targeting of bisantrene by directed intravascular precipitation.
Kovach JS; Buck M; Tsukamoto T; Odegaard A; Lieber MM
Cancer Chemother Pharmacol; 1985; 15(3):192-5. PubMed ID: 4053264
[TBL] [Abstract][Full Text] [Related]
11. Interactions of the antitumor agents mitoxantrone and bisantrene with deoxyribonucleic acids studied by electron microscopy.
Lown JW; Hanstock CC; Bradley RD; Scraba DG
Mol Pharmacol; 1984 Jan; 25(1):178-84. PubMed ID: 6708933
[TBL] [Abstract][Full Text] [Related]
12. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
13. Light, fluorescent, and electron microscopic analysis of cultured breast tumor cells (T-47D) treated with 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride.
Tseng MT; Safa AR
Cancer Res; 1983 Dec; 43(12 Pt 1):5910-4. PubMed ID: 6640539
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical and pharmacokinetic study of bisantrene in refractory pediatric solid tumors.
Pratt CB; Sinkule JA; Etcubanas E; Douglass EC; Crom DB; Choi K; Avery L
Invest New Drugs; 1986; 4(2):149-53. PubMed ID: 3733375
[TBL] [Abstract][Full Text] [Related]
15. Phase II evaluation of bisantrene in metastatic breast cancer.
Cavalli F; Gerard B; ten Bokkel Huinink W; Clavel M; Rozencweig M
Cancer Treat Rep; 1985 Mar; 69(3):337-8. PubMed ID: 3978661
[No Abstract] [Full Text] [Related]
16. Tissue distribution kinetics of a new nonsteroidal 5 alpha-reductase [correction of 5 A-reductase] inhibitor, 4-[3-[3-[bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-YL ]-butyric acid, in rats.
Katashima M; Yamamoto K; Haraguchi K; Tokuma Y; Hata T; Sawada Y; Iga T
Drug Metab Dispos; 1997 Sep; 25(9):1051-8. PubMed ID: 9311620
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
Thompson KL; Vincent SH; Miller RR; Colletti AE; Alvaro RF; Wallace MA; Feeney WP; Chiu SH
Drug Metab Dispos; 1997 Oct; 25(10):1113-8. PubMed ID: 9321512
[TBL] [Abstract][Full Text] [Related]
18. Immunoreactivity and pharmacokinetics of horse anti-scorpion venom F(ab')2-scorpion venom interactions.
Pépin-Covatta S; Lutsch C; Grandgeorge M; Lang J; Scherrmann JM
Toxicol Appl Pharmacol; 1996 Nov; 141(1):272-7. PubMed ID: 8917700
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics of cefamandole in rabbits].
Klimova VS; Bobrov VI; Nazarova OI; Skala LZ; Iakovlev VP
Antibiotiki; 1982 Dec; 27(12):34-8. PubMed ID: 7165292
[TBL] [Abstract][Full Text] [Related]
20. Molecular pharmacology of the anthracycline drug 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1 H-imidazol-2-yl)hydrazone] dihydrochloride (Cl 216,942).
Bowden GT; Garcia D; Peng YM; Alberts DS
Cancer Res; 1982 Jul; 42(7):2660-5. PubMed ID: 7083158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
